siRNA therapy reduces triglycerides in patients along with rare disorder

.STUDY HIGHLIGHT.19 September 2024.

Plozasiran decreased triglyceride degrees by 80% and also decreased the danger of pancreatitis in patients with chronic chylomicronemia, with or without a genetic medical diagnosis.